Mental or Behavioral Dysfunction – Page 6

Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action

9 months ago talkbio0Tagged Antipsychotic Agents, Approved, Cobenfy, Muscarinic Acetylcholine Receptor, Myers, Schizophrenia, squibb, trospium chloride, United States Food and Drug Administration, xanomeline

Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

9 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

Relmada Therapeutics Considers Strategic Alternatives Following Depression Drug Setbacks

9 months ago talkbio0Tagged Blocker, Depressive disorder, Mental Depression, NMDA receptor, REL-1017, Relmada, Sales - occupational activity, strategic alternatives

Relmada Therapeutics, depression drug, REL-1017, strategic alternatives, sale, major depressive disorder, NMDA receptor blocker

Relmada Therapeutics Reassesses Strategy Following Discontinuation of Two Phase 3 Trials for REL-1017

9 months ago talkbio0Tagged Clinical Trials, Drug Development, MDD, Phase 3 trials, REL-1017, Relmada, Strategic Options, Unipolar Depression

Relmada Therapeutics, REL-1017, Phase 3 trials, Major Depressive Disorder (MDD), strategic options, clinical trials, drug development

Lil Jon Teams Up with Singing Toilet for Unconventional Cancer Awareness Campaign

9 months ago talkbio0Tagged cancer kit, Coprophilia (disorder), Lil Jon, promotional campaign, Science, Singing, Toilet procedure

Lil Jon, scat rap, singing toilet, Exact Sciences, cancer kit, promotional campaign

AstraZeneca Addresses Safety Concerns Over Andexxa, Discontinues Opioid Use Disorder Drug

10 months ago talkbio0Tagged Andexxa, Anticoagulation Therapy, AstraZeneca, concerns, Opioid Use Disorder, Reversal, Safety, United States Food and Drug Administration

AstraZeneca, Andexxa, FDA, Safety Concerns, Anticoagulation Reversal, Opioid Use Disorder, AZD4041

AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction

10 months ago talkbio0Tagged Antifungal Agents, AstraZeneca, Clinical Trials, Drug Development, Opioid Use Disorder, Social Interaction

AstraZeneca, Opioid Use Disorder, Drug Development, Antifungal Interaction, Clinical Trials

Cybin’s Psychedelic Drug CYB003 Demonstrates Sustained Efficacy in Reducing Depression Symptoms Over 12 Months

10 months ago talkbio0Tagged Analog, CYB003, Effectiveness, Hallucinogens, MDD, Mental Depression, Sustained, Symptom reduction, Unipolar Depression

CYB003, psychedelic drug, depression treatment, sustained efficacy, 12-month symptom reduction, major depressive disorder (MDD), psilocin analog.

AbbVie’s Schizophrenia Drug Fails in Phase II Trials, Casting Doubt on Neuroscience Strategy

10 months ago talkbio0Tagged AbbVie, Cerevel, Drug Industry, Emraclidine, Neuroscience discipline, Phase 2 Clinical Trials, Schizophrenia

AbbVie, schizophrenia, emraclidine, Phase II trials, Cerevel Therapeutics, neuroscience strategy, pharmaceutical industry

Biogen and Sage Discontinue Plans for Major Depressive Disorder Approval for Zurzuvae

11 months ago talkbio0Tagged Approved, Biogen, Depression, Postpartum, Depressive disorder, United States Food and Drug Administration, Zurzuvae

Biogen, Sage Therapeutics, Zurzuvae, postpartum depression, major depressive disorder, FDA approval